Elebsiran sodium（Cat No.:I043410）is an investigational RNA-based therapeutic designed to target and inhibit the synthesis of apoB-100, a protein essential for the production of low-density lipoprotein (LDL) cholesterol. By reducing apoB-100 levels, Elebsiran aims to lower LDL cholesterol, which is a key contributor to cardiovascular diseases such as atherosclerosis. Elebsiran works through RNA interference (RNAi) to selectively silence the gene responsible for producing apoB-100, offering a novel approach to managing high cholesterol. It is currently being evaluated in clinical trials for its safety, efficacy, and potential to reduce cardiovascular risk.